Shanghai Pharmaceutical Klinmycin capsules were evaluated by generic consistency

On September 14, Shanghai Pharmaceuticals announced that its controlling subsidiary, New Asia Bank, had received a "Notice of Approval of Drug Supplemental Application" (notice number: 2020B04527) issued by the State Drug Administration for Klinmycin capsules, and that the drug had been evaluated consistently through generic drugs.
hydrochloride capsules, which are mainly used for severe infections caused by sensitive anaerobic bacteria, were developed by Pharmacia and Upjohn Co. and first launched in the United States in 1970.
January 2019, the new ADB applied to the State Drug Administration for a consistent evaluation of the drug's generics and was accepted.
not be sold until 2019.
, the main manufacturers of the drug in China are Chongqing Pharmaceuticals Pharmaceutical Co., Ltd., Sichuan Colum Pharmaceutical Co., Ltd., Yichang Renfu Pharmaceutical Co., Ltd.
IQVIA database, the purchase amount of the oral dosage hospital for the drug in 2019 was RMB554.26 million, of which RMB19.01 million was purchased for the capsule hospital.
Shanghai Pharmaceuticals has invested about RMB693.64 million in research and development for the consistent evaluation of the drug.
source: Shanghai Pharmaceutical Bulletin